id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dhrp-29	Rao, Sohail; Singh, Manish	Will Molnupiravir be the First Oral Treatment for High-Risk Non-Hospitalized Patients with Mild-Moderate COVID-19?	2021	2	.pdf	application/pdf	1255	58	32	In a recent non-peer reviewed article, Fischer, et.al., have claimed that Molnupiravir – an experimental anti-viral agent when administered orally in patients with mild to moderated SARS-CoV-2 infection reduced the risk of hospitalization or death by about 50% as compared to the placebo (5). These observations prompted a recent news release by Merck (who developed Molnupiravir in partnership with Ridgeback Biotherapeutics) indicating that they will be submitting an investigational new drug application to the FDA seeking EUA for oral treatment of patients with mild-moderate COVID- 19 (6).	cache/dhrp-29.pdf	txt/dhrp-29.txt